Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Jan;42(1):e3928.
doi: 10.1002/cbf.3928.

The emerging role of USP29 in cancer and other diseases

Ru Zhang  1   2 , Zeqiong Cai  2 , Doudou Ren  2 , Ye Kang  2 , Qi Zhang  3 , Xinlan Lu  1 , Rongfu Tu  2
Affiliations
Review

The emerging role of USP29 in cancer and other diseases

Ru Zhang et al. Cell Biochem Funct. 2024 Jan.

Abstract

Reversible protein ubiquitination is a key process for maintaining cellular homeostasis. Deubiquitinases, which can cleave ubiquitin from substrate proteins, have been reported to be deeply involved in disease progression ranging from oncology to neurological diseases. The human genome encodes approximately 100 deubiquitinases, most of which are poorly characterized. One of the well-characterized deubiquitases is ubiquitin-specific protease 29 (USP29), which is often upregulated in pathological tissues and plays important roles in the progression of different diseases. Moreover, several studies have shown that deletion of Usp29 in mice does not cause visible growth and developmental defects, indicating that USP29 may be an ideal therapeutic target. In this review, we provide a comprehensive summary of the important roles and regulatory mechanisms of USP29 in cancer and other diseases, which may help us better understand its biological functions and improve future studies to construct suitable USP29-targeted therapy systems.

Keywords: USP29; cancer; deubiquitination; protein stability; target therapy.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

REFERENCES

    1. Schubert U, Antón LC, Gibbs J, Norbury CC, Yewdell JW, Bennink JR. Rapid degradation of a large fraction of newly synthesized proteins by proteasomes. Nature. 2000;404:770-774. doi:10.1038/35008096
    1. Rock KL, Gramm C, Rothstein L, et al. Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules. Cell. 1994;78:761-771. doi:10.1016/s0092-8674(94)90462-6
    1. Bedford L, Lowe J, Dick LR, Mayer RJ, Brownell JE. Ubiquitin-like protein conjugation and the ubiquitin-proteasome system as drug targets. Nat Rev Drug Discovery. 2011;10:29-46. doi:10.1038/nrd3321
    1. Liu J, Shaik S, Dai X, et al. Targeting the ubiquitin pathway for cancer treatment. Biochim Biophys Acta (BBA) Rev Cancer. 2015;1855:50-60. doi:10.1016/j.bbcan.2014.11.005
    1. Harris LD, Jasem S, Licchesi JDF. The ubiquitin system in Alzheimer's disease. Adv Exp Med Biol. 2020;1233:195-221. doi:10.1007/978-3-030-38266-7_8